Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03671590
Title Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
TG Therapeutics Investigational Trial Site East Melbourne Victoria Australia Details
TG Therapeutics Investigational Trial Site Fitzroy Victoria Australia Details
TG Therapeutics Investigational Trial Site Nedlands Western Australia Australia Details
TG Therapeutics Investigational Trial Site Adelaide Australia Details
TG Therapeutics Investigational Trial Site Kraków 30-510 Poland Details
TG Therapeutics Investigational Trial Site Lublin 20-090 Poland Details
TG Therapeutics Investigational Trial Site Warszawa 02-781 Poland Details
TG Therapeutics Investigational Trial Site Wrocław 50-367 Poland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field